Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

Core Viewpoint - The U.S. Patent and Trademark Office's PTAB upheld 23 claims of Seer's U.S. Patent No. 11,435,360, affirming the validity of the technology behind Seer's Proteograph® Product Suite [1][3]. Patent Details - The '360 Patent encompasses methods for analyzing biological samples using engineered nano- and microparticles, which enhance protein enrichment essential for Seer's Proteograph platform [2]. - Out of 29 claims, 23 remain valid, including 5 challenged claims and 18 unchallenged claims, protecting Seer's nanoparticle protein enrichment technology [3]. Technology and Market Position - The upheld claims focus on detecting proteins across a broad concentration range and particle-related aspects of Seer's technology, facilitating deep proteomic analysis [3]. - Seer's Proteograph Product Suite combines proprietary engineered nanoparticles, automation instrumentation, and analytical software, enabling scalable and unbiased proteomics [4]. - The company holds an extensive intellectual property portfolio with over 240 issued patents and pending applications globally, including 80 issued patents [4]. Company Overview - Seer, Inc. is recognized for setting standards in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [5].